Clinical trials: Autoimmunity
Diabetes Mellitus, Type 1, Diabetic Polyneuropathy
Effect of C-Peptide on Diabetic Peripheral Neuropathy
The aim of the study is to investigate the effect of C-peptide administration on nerve function in patients with type 1 diabetes and peripheral sensory neuropathy.
- Trial name
- NCT00278980
- Testing
- C-peptide
- Where
- Sweden
- Volunteers
- 180 people
- Sponsor
- Creative Peptides Sweden Inc.
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron
The primary aim of this study is to evaluate the impact of titration, analgesics, and 12 month telephone follow-up period from the B.E.T.A nurse program upon adherence to treatment with Betaseron in patients with a first clinical…
- Trial name
- START (NCT00461396)
- Testing
- Interferon-1beta (Betaseron, BAY86-5046)
- Where
- 19 sites in United States
- Volunteers
- 104 people
- Sponsor
- Bayer
Multiple Sclerosis
A Study to Evaluate the Real-world Experience and Satisfaction Associated With Ofatumumab
The aim of this study was to assess physician and patient satisfaction with ofatumumab using data collected from physicians and their multiple sclerosis (MS) patients in real-world clinical practice across the United Kingdom…
- Trial name
- NCT07504783
- Where
- Switzerland
- Volunteers
- 261 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis
Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis
Demonstrate equivalent efficacy of GP2015 and EU-authorized Enbrel in patients with moderate to severe, active (RA) who had an inadequate response to disease modifying anti-rheumatic drugs (DMARD) including methotrexate (MTX).
- Trial name
- EQUIRA (NCT02638259)
- Testing
- GP2015
- Where
- 92 sites in United States, Bulgaria and 14 more
- Volunteers
- 376 people
- Sponsor
- Sandoz
Lupus Erythematosus, Systemic
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE).
- Trial name
- TOPAZ-1 (NCT04895241)
- Testing
- Litifilimab
- Where
- 164 sites in United States, Australia and 13 more
- Volunteers
- 548 people
- Sponsor
- Biogen
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus
This is an open label, two-arm, randomized multi-center clinical device study in adult subjects with Type 1 diabetes (T1D) or insulin-dependent Type 2 diabetes (T2D) on a multiple daily injection (MDI) regime.
- Trial name
- NCT06704672
- Testing
- Accu-Chek SmartGuide CGM Solution, Accu-Chek SmartGuide Sensor and Blinded Apps, SMBG Device
- Where
- 20 sites in Poland, Turkey (Türkiye)
- Volunteers
- 270 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis
PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers
This is a Phase 1, single-center, open-label, adaptive-design PET study to investigate the occupancy of brain muscarinic Type 1 receptors (M1AChR) by PIPE-307 in healthy volunteers.
- Trial name
- NCT04941781
- Testing
- PIPE-307
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Contineum Therapeutics
Liver Diseases, Primary Biliary Cirrhosis
Repeatability and Reproducibility of Multiparametric MRI
This study aims to prospectively assess the repeatability and reproducibility of iron-corrected T1 (cT1), T2*, and hepatic proton density fat fraction (PDFF) quantification with multiparametric MRI using the LiverMultiScan™ (LMS…
- Conditions
- Liver Diseases, Primary Biliary Cirrhosis, Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
- Trial name
- NCT03743272
- Testing
- LiverMultiScan
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Perspectum
Crohn's Disease, Rheumatoid Arthritis
An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY)
For public health purposes disability is becoming increasingly important as an outcome measure. Despite this, there are few data on the effectiveness of adalimumab on disability outcomes in patients with immune-mediated…
- Conditions
- Crohn's Disease, Rheumatoid Arthritis, Psoriasis
- Trial name
- VITALITY (NCT02451839)
- Volunteers
- 168 people
- Sponsor
- AbbVie
Relapsed/Refractory Autoimmune Diseases
A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases
This is a prospective, single-arm, open-label and dose-escalation Investigator Initialed study to evaluate LUCAR-DKS1 in adult subjects with relapsed/refractory autoimmune diseases.
- Trial name
- NCT07095075
- Testing
- LUCAR-DKS1 NK cells
- Where
- 5 sites in China
- Volunteers
- 36 people
- Sponsor
- Nanjing Legend Biotech Co.
Multiple Sclerosis, Myasthenia Gravis
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or…
- Trial name
- NCT06220201
- Testing
- CC-97540, Fludarabine, Cyclophosphamide
- Where
- 34 sites in United States, Belgium and 4 more
- Volunteers
- 120 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Thrombocytopenia, Immune, Heparin Induced Thrombocytopenia
A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
The purpose of this study is to evaluate the efficacy and safety of VLX-1005, a 12-lipoxygenase (12-LOX) enzyme inhibitor in treating heparin induced thrombocytopenia (HIT).
- Trial name
- NCT05785819
- Testing
- VLX-1005
- Where
- 14 sites in United States
- Volunteers
- 24 people
- Sponsor
- Veralox Therapeutics
Diabetes Mellitus, Type 1
Evaluate the Efficacy of Insulin Patients With Type 1 Diabetes
A study to test for non-inferiority of preprandial HIIP [also known as AIR® Inhaled Insulin Powder][AIR® is a registered trademark of Alkermes,Inc.] compared with preprandial injectable insulin (insulin lispro) with respect to…
- Trial name
- NCT00356109
- Testing
- Human Insulin Inhalation Powder, Injectable insulin, Insulin Glargine
- Where
- 37 sites in United States, Argentina and 7 more
- Volunteers
- 494 people
- Sponsor
- Eli Lilly and Company
Health, Subjective, Gastrointestinal Dysfunction
Personal Lifestyle Engine (PLX) - Personal Lifestyle Medicine Center (PLMC)
It has been suggested that the best medicine should include four principles (4P) - Medicine should be personalized, predictive, preventative and participatory.
- Conditions
- Health, Subjective, Gastrointestinal Dysfunction, Cardiovascular Risk Factor, Autoimmune Diseases
- Trial name
- NCT04007939
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Metagenics, Inc.
Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G)
Chinese Adults With Kidney Disease
This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases.
- Conditions
- Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G), IC-MPGN
- Trial name
- NCT07522099
- Testing
- ADX-038, Telitacicept
- Where
- 9 sites in China
- Volunteers
- 30 people
- Sponsor
- ADARx Pharmaceuticals, Inc.
Type 1 Diabetes
A Study to Compare Pharmacokinetics (PK) and Pharmacodynamics (PD) of SAR341402 to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus
Primary Objective: To compare exposure and activity of SAR341402 to NovoRapid® and NovoLog®. Secondary Objective: To assess the safety and tolerability of SAR341402.
- Trial name
- NCT03202875
- Testing
- SAR341402, Insulin Aspart
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Sanofi
Hashimoto Disease
Single Ascending and Multiple Dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male and Female Adult Subjects
Double-blind, placebo-controlled, single ascending and multiple dose study. Approximately 32 healthy adult male and female subjects will be given a single capsule of MYMD1 to determine its safety, tolerability, and…
- Trial name
- NCT05077865
- Testing
- MYMD-1
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- TNF Pharmaceuticals, Inc.
Type 1 Diabetes
Autologous Immunoregulatory Dendritic Cells for Type 1 Diabetes Therapy
The purpose of this study is to determine whether dendritic cells collected via leukapheresis and incubated with antisense DNA oligonucleotides and then injected back into the same subject will serve as modulators of the immune…
- Trial name
- NCT02354911
- Testing
- Immunoregulatory Dendritic Cells
- Sponsor
- DiaVacs, Inc.
Systemic Lupus Erythematosus
WEUKBRE5716: Steroid-related Damage in Systemic Lupus Erythematosus (Hopkins)
The study is designed to assess the association between steroid exposure and five potentially steroid-related adverse events within a cohort of individuals with systemic lupus erythematosus (SLE).
- Trial name
- NCT01616472
- Testing
- Cumulative corticosteroid exposure
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Systemic Lupus Erythematosus
PRV-3279-2a Trial in Systemic Lupus
The PREVAIL-2 study was designed to assess the safety and potential efficacy of PRV-3279 in flare prevention in systemic lupus erythematosus (SLE) participants with active disease after amelioration induced by corticosteroid…
- Trial name
- PREVAIL-2 (NCT05087628)
- Testing
- PRV-3279
- Where
- 36 sites in United States, China and 2 more
- Volunteers
- 28 people
- Sponsor
- Provention Bio, a Sanofi Company